Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

University of Alabama at Birmingham · with Merck Sharp & Dohme LLC · NCT07135453

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
70
US sites recruiting
1
Study start
July 1, 2026
Record last updated
August 21, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria.

We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.

Being studied: Pneumococcal Vaccine

Conditions: Vaccine; Pneumococcal Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Healthy adult

Exclusion Criteria

  • No prior history of pneumococcal vaccination
  • No immunosuppressing medications or chronic diseases that affect immune function

Recruiting US locations

  • University of Alabama at Birmingham

    Birmingham, AL 35294

    Site contact: LaFon, MD · 2059343411 · dlafon@uabmc.edu

Study contacts (from the official record)

  • David LaFon, MD · 2059343411 · dlafon@uabmc.edu
All vaccine studies in Alabama →
Induction of Cross-protective Antibodies for Serogroup 33 by… (NCT07135453) | Bored Studies